Entropy Neurodynamics Granted Australian Patent for Psilocin Crystalline Forms
MT Newswires Live
Jul 10
Entropy Neurodynamics (ASX:ENP) said the Australian Patent Office has granted it an Australian patent titled Psilocin Crystalline Forms, providing composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve its stability, solubility, and pharmaceutical properties, according to a Friday Australian bourse filing.
The company said the patent claims also cover manufacturing methods, pharmaceutical formulations, and therapeutic applications across a range of neuropsychiatric disorders, with the patent remaining in force until September 2043.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.